<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764828</url>
  </required_header>
  <id_info>
    <org_study_id>14747</org_study_id>
    <nct_id>NCT01764828</nct_id>
  </id_info>
  <brief_title>BAY86-9766 Plus Gemcitabine Phase I Study in Asian</brief_title>
  <official_title>A Multi-center, Phase Ib Study of MEK (Mitogen Activated Protein Kinase/ERK Kinase) Inhibitor BAY86-9766 Plus Gemcitabine in Asian Patients With Advanced or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, uncontrolled, Phase Ib study designed to evaluate the safety,
      tolerability, and pharmacokinetics of BAY86-9766 when given as a single agent and in
      combination with gemcitabine in Asian patients with advanced or refractory solid tumors.Blood
      samples for PK (pharmacokinetics) analyses will be collected after a single dose of
      BAY86-9766, multiple doses of BAY86-9766, and combination treatment of gemcitabine and
      BAY86-9766.

      Safety evaluation will include adverse events assessment, vital signs, laboratory tests,
      12-lead ECG ECG (electrocardiography), cardiac function test, and ophthalmologic examination
      at various time points during the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of BAY86-9766</measure>
    <time_frame>Multiple time points up to 6 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of M17 and M11</measure>
    <time_frame>Multiple time points up to 6 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Gemcitabine</measure>
    <time_frame>Multiple time points up to 6 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of dFdU</measure>
    <time_frame>Multiple time points up to 6 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events, or abnormal parameters as a measure of safety and tolerability</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Parameters are laboratory parameters, vital signs, ECG parameters, cardiac function, and parameters of ophthalmologic examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of BAY86-9766 shown by a discrete scale</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Elements of the scale are :Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Refametinib (BAY86-9766)+ Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refametinib (BAY86-9766)</intervention_name>
    <arm_group_label>Refametinib (BAY86-9766)+ Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Refametinib (BAY86-9766)+ Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients &gt;/= 18 years of age, with histologically or cytologically
             documented advanced or refractory solid tumors not amenable to standard therapy

          -  Patients must have at least one measurable or evaluable tumor lesion according to
             Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

          -  Patients must have a life expectancy of at least 12 weeks, and an Eastern Cooperative
             Oncology Group Performance Status (ECOG PS) &lt;/=1.

        Exclusion Criteria:

          -  History of cardiac disease

          -  Active clinically serious infections &gt; Common Terminology Criteria for Adverse Events
             (CTCAE) grade 2

          -  Known human immunodeficiency virus (HIV) infection

          -  Uncontrolled seizure disorder

          -  Undergoing renal dialysis

          -  Known bleeding diathesis

          -  History of organ allograft

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety measurements</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

